Literature DB >> 9387044

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

T Suzuki1, S Minamide, T Iwasaki, H Yamamoto, H Kanda.   

Abstract

The degree of cardiotoxicity of SM-5887 compared with that of doxorubicin was investigated in rabbits. Two experimental groups were administered high and low doses of SM-5887, respectively. One group was administered doxorubicin and another group was administered the vehicle only were prepared as positive and negative controls, respectively. Drugs were intravenously administered 3 times a week for 8 weeks. At terminus, electrocardiograms were recorded under anesthesia. The blood was collected for haematology and blood biochemistry analyses. Myocardial tissue damage was evaluated using light and electron microscopy. In the electrocardiogram study, prolongation of QTc interval and ST-T change were observed in rabbits administered SM-5887 and doxorubicin. Morphological studies showed that myocardial tissue damage in animals administered SM-5887 was comparable to that in the negative controls, and less than that observed in the positive controls. The general toxicological investigations uniformly indicated lower toxicity in the SM-5887 group than in the doxorubicin group at equivalent dosages. In total, considering the results of antitumor efficacy studies comparing SM-5887 with doxorubicin, these results indicate that the cardiotoxicity of SM-5887 is very slight, and that the general toxicity of SM-5887 is lower than that of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387044     DOI: 10.1023/a:1005862730941

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  7 in total

1.  Cardiotoxicity of anthracycline antineoplastic drugs--Clinicopathological and experimental studies.

Authors:  T Suzuki; H Kanda; Y Kawai; K Tominaga; K Murata
Journal:  Jpn Circ J       Date:  1979-11

Review 2.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

Review 3.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity.

Authors:  V J Ferrans
Journal:  Cancer Treat Rep       Date:  1978-06

4.  Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.

Authors:  C Bertazzoli; O Bellini; U Magrini; M G Tosana
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

5.  [A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].

Authors:  T Suzuki; H Yamamoto; T Iwasaki; S Okamoto; T Iizuka; H Kanda; K Murata
Journal:  Gan To Kagaku Ryoho       Date:  1984-10

6.  Toxicological aspects of a novel 9-aminoanthracycline, SM-5887.

Authors:  S Morisada; Y Yanagi; Y Kashiwazaki; M Fukui
Journal:  Jpn J Cancer Res       Date:  1989-01

7.  Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts.

Authors:  S Morisada; Y Yanagi; T Noguchi; Y Kashiwazaki; M Fukui
Journal:  Jpn J Cancer Res       Date:  1989-01
  7 in total
  19 in total

1.  Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.

Authors:  Tomonobu Koizumi; Toshihiko Agatsuma; Takashi Ichiyama; Toshiki Yokoyama; Atsuhito Ushiki; Yoshimichi Komatsu; Tsuyoshi Tanabe; Takashi Kobayashi; Sumiko Yoshikawa; Masanori Yasuo; Hiroshi Yamamoto; Keishi Kubo; Tsutomu Hachiya
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

2.  Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.

Authors:  Takahiko Sugiura; Yutaka Ariyoshi; Shunichi Negoro; Shinichiro Nakamura; Harumichi Ikegami; Minoru Takada; Takashi Yana; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

3.  Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.

Authors:  Toshiyuki Sawa; Takashi Yana; Minoru Takada; Takahiko Sugiura; Shinzoh Kudoh; Tadashi Kamei; Takeshi Isobe; Hidehiko Yamamoto; Soichiro Yokota; Nobuyuki Katakami; Yuji Tohda; Akira Kawakami; Yoichi Nakanishi; Yutaka Ariyoshi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

Review 4.  The role of anthracyclines in small cell lung cancer.

Authors:  Ana López-González; Pilar Diz; Lourdes Gutierrez; Elena Almagro; Andrés García Palomo; Mariano Provencio
Journal:  Ann Transl Med       Date:  2013-04

5.  Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report.

Authors:  Hiroaki Satoh; Norio Takayashiki; Toshihiro Shiozawa; Kunihiko Miyazaki; Gen Ohara; Katsunori Kagohashi; Koichi Kurishima; Shintaro Sugita; Tomoyuki Aoyama; Tadashi Hasegawa; Nobuyuki Hizawa
Journal:  Exp Ther Med       Date:  2015-02-24       Impact factor: 2.447

6.  Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.

Authors:  Sumati Gupta; Launce Gouw; Jennifer Wright; Sant Chawla; Debbie Pitt; Mark Wade; Ken Boucher; Sunil Sharma
Journal:  Invest New Drugs       Date:  2016-02-20       Impact factor: 3.850

7.  Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Koji Takeda; Nobuhide Takifuji; Shunichi Negoro; Kiyoyuki Furuse; Shinichiro Nakamura; Yoshiki Takada; Takanobu Hoso; Shinichi Hayasaka; Takashi Nakano; Jun Araki; Hiroshi Senba; Fumiyuki Iwami; Yasufumi Yamaji; Masahiro Fukuoka; Harumichi Ikegami
Journal:  Invest New Drugs       Date:  2007-03-10       Impact factor: 3.850

Review 8.  Can anthracycline therapy for pediatric malignancies be less cardiotoxic?

Authors:  Joy M Fulbright; Winston Huh; Pete Anderson; Joya Chandra
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 9.  Amrubicin for non-small-cell lung cancer and small-cell lung cancer.

Authors:  Takayasu Kurata; Isamu Okamoto; Kenji Tamura; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2007-07-13       Impact factor: 3.850

10.  Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin.

Authors:  Michiko Yamamoto; Akira Takakura; Noriyuki Masuda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.